Please login to the form below

Not currently logged in

Ex-Pfizer research head Dr David Roblin joins Destiny Pharma

The former head of research at Pfizer's European operations will be medical director at Destiny

Anti-microbial drug development company Destiny Pharma has appointed ex-Pfizer research head Dr David Roblin as medical director.

He headed up Pfizer's European research operations in Sandwich, Kent until March 2011 when he left following the company's announcement it would close the UK research site with the loss of 2,400 jobs.

Dr Roblin said: “After leaving Pfizer I wanted to work with smaller companies where I believe there is a good chance to bring important new medicines to patients and value to investors.

“I was attracted to the science coming out of Destiny. It is creating a class of antibiotics unique in its rapid activity and its efficacy on resistant organisms that are causing many problems in medical practice. This is a step change in antimicrobials and one I am very exciting about contributing to.”

He brings to Destiny 15 years' experience in senior R&D roles at Pfizer and Bayer and five years' experience of medical practice.

Dr Roblin will be joined at Destiny by Sir Nigel Rudd, the former head of BAA and ex-chief of Boots.

Based at the Sussex Innovation Centre near Brighton in the UK, Destiny focuses on anti-microbial drug development and its lead product, XF-73, targets antibiotic resistant strains of Staphylococcus aureus like MRSA.

7th November 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

5 tactics to master Market Access
Is it time to rethink your game plan? To succeed at Market Access, follow these 5 tactics:...
Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards